ACTA1 and metabolic dysfunction-associated steatotic liver disease: Also, studies have reported the presence of autoimmune markers (ANA, AMA, and anti-smooth muscle antibodies (ASMA)) in MASLD at a higher prevalence than in the general population, ranging from 12% to 48% [3].